Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    October 2017
  1. NORGARD BM, Magnussen B, Larsen MD, Friedman S, et al
    Reassuring results on birth outcomes in children fathered by men treated with azathioprine/6-mercaptopurine within 3 months before conception: a nationwide cohort study.
    Gut. 2017;66:1761-1766.
    PubMed     Text format     Abstract available


    September 2017
  2. BERTIN S, Aoki-Nonaka Y, Lee J, de Jong PR, et al
    The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1.
    Gut. 2017;66:1584-1596.
    PubMed     Text format     Abstract available


    August 2017
  3. PARIAN A, Limketkai B, Koh J, Brant SR, et al
    Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.
    Gut. 2017;66:1390-1397.
    PubMed     Text format     Abstract available


  4. NYBOE ANDERSEN N, Gortz S, Frisch M, Jess T, et al
    Reduced risk of UC in families affected by appendicitis: a Danish national cohort study.
    Gut. 2017;66:1398-1402.
    PubMed     Text format     Abstract available


  5. O'BRIEN CL, Bringer MA, Holt KE, Gordon DM, et al
    Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli.
    Gut. 2017;66:1382-1389.
    PubMed     Text format     Abstract available


    June 2017
  6. PANES J, Sandborn WJ, Schreiber S, Sands BE, et al
    Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Gut. 2017;66:1049-1059.
    PubMed     Text format     Abstract available


  7. SCHWERD T, Pandey S, Yang HT, Bagola K, et al
    Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
    Gut. 2017;66:1060-1073.
    PubMed     Text format     Abstract available


  8. SOKOL H, Leducq V, Aschard H, Pham HP, et al
    Fungal microbiota dysbiosis in IBD.
    Gut. 2017;66:1039-1048.
    PubMed     Text format     Abstract available


    May 2017
  9. PARANG B, Kaz AM, Barrett CW, Short SP, et al
    BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.
    Gut. 2017;66:852-862.
    PubMed     Text format     Abstract available


  10. PASCAL V, Pozuelo M, Borruel N, Casellas F, et al
    A microbial signature for Crohn's disease.
    Gut. 2017;66:813-822.
    PubMed     Text format     Abstract available


  11. LEE T, Clavel T, Smirnov K, Schmidt A, et al
    Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.
    Gut. 2017;66:863-871.
    PubMed     Text format     Abstract available


  12. SCHEIBE K, Backert I, Wirtz S, Hueber A, et al
    IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.
    Gut. 2017;66:823-838.
    PubMed     Text format     Abstract available


    April 2017
  13. LIN W, Ma C, Su F, Jiang Y, et al
    Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice.
    Gut. 2017;66:597-610.
    PubMed     Text format     Abstract available


    February 2017
  14. NOBEN M, Verstockt B, de Bruyn M, Hendriks N, et al
    Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?
    Gut. 2017 Feb 3. pii: gutjnl-2016-313667. doi: 10.1136/gutjnl-2016-313667.
    PubMed     Text format    


  15. SUBRAMANIAN S, Ekbom A, Rhodes JM
    Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?
    Gut. 2017;66:362-381.
    PubMed     Text format     Abstract available


  16. CASTANO-RODRIGUEZ N, Kaakoush NO, Lee WS, Mitchell HM, et al
    Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis.
    Gut. 2017;66:235-249.
    PubMed     Text format     Abstract available


    January 2017
  17. MOSLI MH, Feagan BG, Zou G, Sandborn WJ, et al
    Development and validation of a histological index for UC.
    Gut. 2017;66:50-58.
    PubMed     Text format     Abstract available


  18. MARCHAL-BRESSENOT A, Salleron J, Boulagnon-Rombi C, Bastien C, et al
    Development and validation of the Nancy histological index for UC.
    Gut. 2017;66:43-49.
    PubMed     Text format     Abstract available


  19. MACHIELS K, Sabino J, Vandermosten L, Joossens M, et al
    Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC.
    Gut. 2017;66:79-88.
    PubMed     Text format     Abstract available


    November 2016
  20. OLIVERA P, Danese S, Peyrin-Biroulet L
    Next generation of small molecules in inflammatory bowel disease.
    Gut. 2016 Nov 17. pii: gutjnl-2016-312912. doi: 10.1136/gutjnl-2016-312912.
    PubMed     Text format    


  21. DOTTI I, Mora-Buch R, Ferrer-Picon E, Planell N, et al
    Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis.
    Gut. 2016 Nov 1. pii: gutjnl-2016-312609. doi: 10.1136/gutjnl-2016-312609.
    PubMed     Text format     Abstract available


    October 2016
  22. IMHANN F, Vich Vila A, Bonder MJ, Fu J, et al
    Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
    Gut. 2016 Oct 8. pii: gutjnl-2016-312135. doi: 10.1136/gutjnl-2016-312135.
    PubMed     Text format     Abstract available


    September 2016
  23. HASLER R, Sheibani-Tezerji R, Sinha A, Barann M, et al
    Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease.
    Gut. 2016 Sep 30. pii: gutjnl-2016-311651. doi: 10.1136/gutjnl-2016-311651.
    PubMed     Text format     Abstract available


    July 2016
  24. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Text format     Abstract available


    May 2016
  25. STARR AE, Deeke SA, Ning Z, Chiang CK, et al
    Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC.
    Gut. 2016 May 23. pii: gutjnl-2015-310705. doi: 10.1136/gutjnl-2015-310705.
    PubMed     Text format     Abstract available


  26. SABINO J, Vieira-Silva S, Machiels K, Joossens M, et al
    Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
    Gut. 2016 May 20. pii: gutjnl-2015-311004. doi: 10.1136/gutjnl-2015-311004.
    PubMed     Text format     Abstract available


  27. QUEVRAIN E, Maubert MA, Sokol H, Devreese B, et al
    The presence of the anti-inflammatory protein MAM, from Faecalibacterium prausnitzii, in the intestinal ecosystem.
    Gut. 2016;65:882.
    PubMed     Text format    


  28. HONG SN, Park C, Park SJ, Lee CK, et al
    Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants.
    Gut. 2016;65:788-96.
    PubMed     Text format     Abstract available


    April 2016
  29. CANAVAN JB, Scotta C, Vossenkamper A, Goldberg R, et al
    Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.
    Gut. 2016;65:584-94.
    PubMed     Text format     Abstract available


    March 2016
  30. ADAMI HO, Bretthauer M, Emilsson L, Hernan MA, et al
    The continuing uncertainty about cancer risk in inflammatory bowel disease.
    Gut. 2016 Mar 23. pii: gutjnl-2015-311003. doi: 10.1136/gutjnl-2015-311003.
    PubMed     Text format    


  31. TURSI A, Principi M, Picchio M, Giorgio F, et al
    Persistence of endoscopic rectal inflammation in UC treated with infliximab is not linked to ineffective TNFalpha downregulation.
    Gut. 2016;65:539-40.
    PubMed     Text format    


  32. HORNEF MW, Pabst O
    Real friends: Faecalibacterium prausnitzii supports mucosal immune homeostasis.
    Gut. 2016;65:365-7.
    PubMed     Text format    


  33. QUEVRAIN E, Maubert MA, Michon C, Chain F, et al
    Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.
    Gut. 2016;65:415-25.
    PubMed     Text format     Abstract available


  34. BRYANT RV, Burger DC, Delo J, Walsh AJ, et al
    Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.
    Gut. 2016;65:408-14.
    PubMed     Text format     Abstract available


    February 2016
  35. NORGARD BM, Larsen PV, Fedder J, de Silva PS, et al
    Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease receiving assisted reproduction: a 20-year nationwide cohort study.
    Gut. 2016 Feb 26. pii: gutjnl-2015-311246. doi: 10.1136/gutjnl-2015-311246.
    PubMed     Text format     Abstract available


  36. COLOMBEL JF, Sands BE, Rutgeerts P, Sandborn W, et al
    The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079.
    PubMed     Text format     Abstract available


  37. KUMMEN M, Holm K, Anmarkrud JA, Nygard S, et al
    The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.
    Gut. 2016 Feb 17. pii: gutjnl-2015-310500. doi: 10.1136/gutjnl-2015-310500.
    PubMed     Text format     Abstract available


  38. MARCHESI JR, Adams DH, Fava F, Hermes GD, et al
    The gut microbiota and host health: a new clinical frontier.
    Gut. 2016;65:330-9.
    PubMed     Text format     Abstract available


  39. CHAMAILLARD M, Radulovic K
    Defining dysbiosis threatens Koch's postulates and current dogma on the role of Paneth cells in Crohn's disease.
    Gut. 2016;65:190-1.
    PubMed     Text format    


  40. SCHAUBECK M, Clavel T, Calasan J, Lagkouvardos I, et al
    Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence.
    Gut. 2016;65:225-37.
    PubMed     Text format     Abstract available


  41. REHMAN A, Rausch P, Wang J, Skieceviciene J, et al
    Geographical patterns of the standing and active human gut microbiome in health and IBD.
    Gut. 2016;65:238-48.
    PubMed     Text format     Abstract available


    December 2015
  42. GOWER-ROUSSEAU C, Sarter H, Savoye G, Tavernier N, et al
    Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort.
    Gut. 2015 Dec 8. pii: gutjnl-2015-310151. doi: 10.1136/gutjnl-2015-310151.
    PubMed     Text format     Abstract available


  43. TURNER D, Doveh E, Cohen A, Wilson ML, et al
    Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study.
    Gut. 2015;64:1898-904.
    PubMed     Text format     Abstract available


  44. ZEISSIG S, Petersen BS, Tomczak M, Melum E, et al
    Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.
    Gut. 2015;64:1889-97.
    PubMed     Text format     Abstract available


    November 2015
  45. MOSLI MH, Feagan BG, Zou G, Sandborn WJ, et al
    Reproducibility of histological assessments of disease activity in UC.
    Gut. 2015;64:1765-73.
    PubMed     Text format     Abstract available


  46. WU W, He C, Liu C, Cao AT, et al
    miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD.
    Gut. 2015;64:1755-64.
    PubMed     Text format     Abstract available


    October 2015
  47. VANDE CASTEELE N, Khanna R, Levesque BG, Stitt L, et al
    The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
    Gut. 2015;64:1539-45.
    PubMed     Text format     Abstract available


  48. SADAGHIAN SADABAD M, Regeling A, de Goffau MC, Blokzijl T, et al
    The ATG16L1-T300A allele impairs clearance of pathosymbionts in the inflamed ileal mucosa of Crohn's disease patients.
    Gut. 2015;64:1546-52.
    PubMed     Text format     Abstract available


    September 2015
  49. DANESE S, Peyrin-Biroulet L, Fiorino G
    Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?
    Gut. 2015;64:1347-8.
    PubMed     Text format    


  50. BOETTLER T, Lutz L, Schmidt N, Thimme R, et al
    An uncommon presentation of a common pathogen.
    Gut. 2015;64:1411.
    PubMed     Text format    


  51. JAUREGUI-AMEZAGA A, Rimola J, Ordas I, Rodriguez S, et al
    Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn's disease in the era of biologics.
    Gut. 2015;64:1397-402.
    PubMed     Text format     Abstract available


  52. BRESSENOT A, Salleron J, Bastien C, Danese S, et al
    Comparing histological activity indexes in UC.
    Gut. 2015;64:1412-8.
    PubMed     Text format     Abstract available


  53. BERNSTEIN CN, Nugent Z, Targownik LE, Singh H, et al
    Predictors and risks for death in a population-based study of persons with IBD in Manitoba.
    Gut. 2015;64:1403-11.
    PubMed     Text format     Abstract available


    August 2015
  54. BOSCHETTI G, Assaad S, Balme B, Boyer S, et al
    A challenging case of multiple splenic and pancreatic lesions in a patient with Crohn's disease.
    Gut. 2015 Aug 5. pii: gutjnl-2015-310130. doi: 10.1136/gutjnl-2015-310130.
    PubMed     Text format    


  55. BILLIET T, Vande Casteele N, Van Stappen T, Princen F, et al
    Immunogenicity to infliximab is associated with HLA-DRB1.
    Gut. 2015;64:1344-5.
    PubMed     Text format    


  56. STEENHOLDT C, Ainsworth MA
    Authors' response: Importance of defining loss of response before therapeutic drug monitoring.
    Gut. 2015;64:1340-1.
    PubMed     Text format    


  57. D'HAENS G, Sandborn WJ, Colombel JF, Rutgeerts P, et al
    A phase II study of laquinimod in Crohn's disease.
    Gut. 2015;64:1227-35.
    PubMed     Text format     Abstract available


    July 2015
  58. CIUCCI T, Ibanez L, Boucoiran A, Birgy-Barelli E, et al
    Bone marrow Th17 TNFalpha cells induce osteoclast differentiation, and link bone destruction to IBD.
    Gut. 2015;64:1072-81.
    PubMed     Text format     Abstract available


  59. SYRBE U, Siegmund B
    Bone marrow Th17 TNFalpha cells induce osteoclast differentiation and link bone destruction to IBD.
    Gut. 2015;64:1011-2.
    PubMed     Text format    


  60. LAKATOS PL, Burisch J
    Environment and invironment in IBDs: partners in crime.
    Gut. 2015;64:1009-10.
    PubMed     Text format    


    June 2015
  61. HART PA, Levy MJ, Smyrk TC, Takahashi N, et al
    Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience.
    Gut. 2015 Jun 17. pii: gutjnl-2015-309275. doi: 10.1136/gutjnl-2015-309275.
    PubMed     Text format     Abstract available


  62. REINISCH W, Panes J, Khurana S, Toth G, et al
    Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
    Gut. 2015;64:894-900.
    PubMed     Text format     Abstract available


  63. BOUGUEN G, Langlois A, Djouina M, Branche J, et al
    Intestinal steroidogenesis controls PPARgamma expression in the colon and is impaired during ulcerative colitis.
    Gut. 2015;64:901-10.
    PubMed     Text format     Abstract available


    May 2015
  64. KHALILI H, Chan AT
    Author response: oral contraceptives and Crohn's disease.
    Gut. 2015;64:854.
    PubMed     Text format    


  65. FU SH, Lin MH, Yeh LT, Wang YL, et al
    Targeting tumour necrosis factor receptor 1 assembly reverses Th17-mediated colitis through boosting a Th2 response.
    Gut. 2015;64:765-75.
    PubMed     Text format     Abstract available


  66. NALLEWEG N, Chiriac MT, Podstawa E, Lehmann C, et al
    IL-9 and its receptor are predominantly involved in the pathogenesis of UC.
    Gut. 2015;64:743-55.
    PubMed     Text format     Abstract available


    April 2015
  67. YANG SK, Ye BD, Song K
    ATG16L1 contributes to Crohn's disease susceptibility in Koreans: overmuch concern for ethnic difference?
    Gut. 2015;64:687-8.
    PubMed     Text format    


  68. JAMES SL, Christophersen CT, Bird AR, Conlon MA, et al
    Abnormal fibre usage in UC in remission.
    Gut. 2015;64:562-70.
    PubMed     Text format     Abstract available


  69. GENUA M, D'Alessio S, Cibella J, Gandelli A, et al
    The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation.
    Gut. 2015;64:589-600.
    PubMed     Text format     Abstract available


    December 2014
  70. JOOSSE ME, Schipper ME, Libbrecht L, Buuren HR, et al
    Recurrent cholangitis in a 65-year-old man.
    Gut. 2014 Dec 22. pii: gutjnl-2014-308726. doi: 10.1136/gutjnl-2014-308726.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: